BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Robert C, Long GV, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Rutkowski P, Hassel JC, McNeil CM, Kalinka EA, Lebbé C, Charles J, Hernberg MM, Savage KJ, Chiarion-Sileni V, Mihalcioiu C, Mauch C, Arance A, Cognetti F, Ny L, Schmidt H, Schadendorf D, Gogas H, Zoco J, Re S, Ascierto PA, Atkinson V. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. J Clin Oncol 2020;38:3937-46. [PMID: 32997575 DOI: 10.1200/JCO.20.00995] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 17.3] [Reference Citation Analysis]
Number Citing Articles
1 Araujo Vargas TP, Al-Humiqani A, Giffoni De Mello Morais Mata D, Menjak IB. Immunotherapy for older patients with cancer. Curr Opin Support Palliat Care 2023;17:37-46. [PMID: 36695867 DOI: 10.1097/SPC.0000000000000637] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 ter Maat L, van Duin I, Elias S, Leiner T, Verhoeff J, Arntz E, Troenokarso M, Blokx W, Isgum I, de Wit G, van den Berkmortel F, Boers-sonderen M, Boomsma M, van den Eertwegh A, de Groot J, Piersma D, Vreugdenhil G, Westgeest H, Kapiteijn E, van Diest P, Pluim J, de Jong P, Suijkerbuijk K, Veta M. CT radiomics to predict checkpoint inhibitors treatment outcomes in patients with advanced cutaneous melanoma.. [DOI: 10.1101/2022.12.19.22283574] [Reference Citation Analysis]
3 Rohaan MW, Borch TH, van den Berg JH, Met Ö, Kessels R, Geukes Foppen MH, Stoltenborg Granhøj J, Nuijen B, Nijenhuis C, Jedema I, van Zon M, Scheij S, Beijnen JH, Hansen M, Voermans C, Noringriis IM, Monberg TJ, Holmstroem RB, Wever LDV, van Dijk M, Grijpink-Ongering LG, Valkenet LHM, Torres Acosta A, Karger M, Borgers JSW, Ten Ham RMT, Retèl VP, van Harten WH, Lalezari F, van Tinteren H, van der Veldt AAM, Hospers GAP, Stevense-den Boer MAM, Suijkerbuijk KPM, Aarts MJB, Piersma D, van den Eertwegh AJM, de Groot JB, Vreugdenhil G, Kapiteijn E, Boers-Sonderen MJ, Fiets WE, van den Berkmortel FWPJ, Ellebaek E, Hölmich LR, van Akkooi ACJ, van Houdt WJ, Wouters MWJM, van Thienen JV, Blank CU, Meerveld-Eggink A, Klobuch S, Wilgenhof S, Schumacher TN, Donia M, Svane IM, Haanen JBAG. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N Engl J Med 2022;387:2113-25. [PMID: 36477031 DOI: 10.1056/NEJMoa2210233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
4 Wang H, Tran TT, Duong KT, Nguyen T, Le UM. Options of Therapeutics and Novel Delivery Systems of Drugs for the Treatment of Melanoma. Mol Pharm 2022;19:4487-505. [PMID: 36305753 DOI: 10.1021/acs.molpharmaceut.2c00775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ferreira A, Neves MT, Baleiras A, Malheiro M, Martins A. Fecal Microbiota Transplant in Immunotherapy-Resistant Melanoma: What Can We Expect in the Near Future? Cureus 2022;14:e32586. [PMID: 36654598 DOI: 10.7759/cureus.32586] [Reference Citation Analysis]
6 Kahlon N, Doddi S, Yousif R, Najib S, Sheikh T, Abuhelwa Z, Burmeister C, Hamouda DM. Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019. JAMA Netw Open 2022;5:e2245269. [PMID: 36472871 DOI: 10.1001/jamanetworkopen.2022.45269] [Reference Citation Analysis]
7 Corrie P, Meyer N, Berardi R, Guidoboni M, Schlueter M, Kolovos S, Macabeo B, Trouiller JB, Laramée P. Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis. Cancer Treat Rev 2022;110:102463. [PMID: 36099854 DOI: 10.1016/j.ctrv.2022.102463] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Guardamagna M, Berciano-Guerrero MA, Villaescusa-González B, Perez-Ruiz E, Oliver J, Lavado-Valenzuela R, Rueda-Dominguez A, Barragán I, Queipo-Ortuño MI. Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition. Int J Mol Sci 2022;23:11990. [PMID: 36233289 DOI: 10.3390/ijms231911990] [Reference Citation Analysis]
9 Antoun S, Lanoy E, Ammari S, Farhane S, Martin L, Robert C, Planchard D, Routier E, Laure Voisin A, Messayke S, Champiat S, Marie Michot J, Laghouati S, Lambotte O, Marabelle A, Baracos V. Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle. European Journal of Cancer 2022. [DOI: 10.1016/j.ejca.2022.10.013] [Reference Citation Analysis]
10 Hermann N, Maul LV, Ameri M, Traidl S, Ziadlou R, Papageorgiou K, Kolm I, Levesque M, Maul J, Brüggen M. Clinical Presentation and Prognostic Features in Patients with Immunotherapy-Induced Vitiligo-like Depigmentation: A Monocentric Prospective Observational Study. Cancers 2022;14:4576. [DOI: 10.3390/cancers14194576] [Reference Citation Analysis]
11 Beasley GM, Brown MC, Farrow NE, Landa K, Al-Rohil RN, Selim MA, Therien AD, Jung SH, Gao J, Boczkowski D, Holl EK, Salama AKS, Bigner DD, Gromeier M, Nair SK. Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma. J Immunother Cancer 2022;10:e005052. [PMID: 36175036 DOI: 10.1136/jitc-2022-005052] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Berciano-guerrero M, Guardamagna M, Perez-ruiz E, Jurado J, Barragán I, Rueda-dominguez A. Treatment of Metastatic Melanoma at First Diagnosis: Review of the Literature. Life 2022;12:1302. [DOI: 10.3390/life12091302] [Reference Citation Analysis]
13 Saiag P, Molinier R, Roger A, Boru B, Otmezguine Y, Otz J, Valery C, Blom A, Longvert C, Beauchet A, Funck-brentano E. Efficacy of Large Use of Combined Hypofractionated Radiotherapy in a Cohort of Anti-PD-1 Monotherapy-Treated Melanoma Patients. Cancers 2022;14:4069. [DOI: 10.3390/cancers14174069] [Reference Citation Analysis]
14 Lin EP, Hsu CY, Berry L, Bunn P, Shyr Y. Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment: A Systematic Review and Meta-analyses. JAMA Netw Open 2022;5:e2227211. [PMID: 35976648 DOI: 10.1001/jamanetworkopen.2022.27211] [Reference Citation Analysis]
15 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
16 Kuzmanovszki D, Kiss N, Tóth B, Kerner T, Tóth V, Szakonyi J, Lőrincz K, Hársing J, Imrédi E, Pfund A, Szabó Á, Brodszky V, Rencz F, Holló P. Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study. Biomedicines 2022;10:1737. [DOI: 10.3390/biomedicines10071737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zhai Y, Dong S, Li H, Zhang Y, Shami P, Chen M. Antibody-mediated depletion of programmed death 1-positive (PD-1+) cells. J Control Release 2022;349:425-33. [PMID: 35820540 DOI: 10.1016/j.jconrel.2022.07.010] [Reference Citation Analysis]
18 Sun H, Li Y, Zeng F, Meng Y, Du S, Deng G. Melanoma survivors are at increased risk for second primary keratinocyte carcinoma. Int J Dermatol 2022. [PMID: 35726477 DOI: 10.1111/ijd.16309] [Reference Citation Analysis]
19 Lastraioli E, Ruffinatti FA, Bagni G, Visentin L, di Costanzo F, Munaron L, Arcangeli A. The Transcriptional Landscape of BRAF Wild Type Metastatic Melanoma: A Pilot Study. IJMS 2022;23:6898. [DOI: 10.3390/ijms23136898] [Reference Citation Analysis]
20 Jing M, Cai Y, Shi J, Zhang X, Zhu B, Yuan F, Zhang J, Xiao M, Chen M. Adjuvant Treatments of Adult Melanoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2022;12:926242. [DOI: 10.3389/fonc.2022.926242] [Reference Citation Analysis]
21 Xiang Z, Li J, Zhang Z, Cen C, Chen W, Jiang B, Meng Y, Wang Y, Berglund B, Zhai G, Wu J. Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis. Front Pharmacol 2022;13:883655. [DOI: 10.3389/fphar.2022.883655] [Reference Citation Analysis]
22 Zhou L, Wu X, Chi Z, Si L, Sheng X, Kong Y, Mao L, Lian B, Tang B, Yan X, Wang X, Bai X, Li S, Wei X, Li J, Yang Q, Guo J, Cui C. Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study. BMC Cancer 2022;22:565. [PMID: 35596181 DOI: 10.1186/s12885-022-09663-5] [Reference Citation Analysis]
23 Homicsko K, Dummer R, Hoeller C, Wolchok JD, Hodi FS, Larkin J, Ascierto PA, Atkinson V, Robert C, Postow MA, Re S, Paulucci D, Dobler D, Michielin O. Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. Cancers 2022;14:2300. [DOI: 10.3390/cancers14092300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Aroldi F, Middleton MR. Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma. Am J Clin Dermatol 2022;23:331-8. [PMID: 35359259 DOI: 10.1007/s40257-022-00681-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Kuske M, Haist M, Jung T, Grabbe S, Bros M. Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses? Cancers (Basel) 2022;14:1710. [PMID: 35406483 DOI: 10.3390/cancers14071710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Jansen Y, van der Veldt AAM, Awada G, Neyns B. Anti-PD-1: When to Stop Treatment. Curr Oncol Rep. [DOI: 10.1007/s11912-022-01264-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Gordon LG, Leung W, Johns R, McNoe B, Lindsay D, Merollini KMD, Elliott TM, Neale RE, Olsen CM, Pandeya N, Whiteman DC. Estimated Healthcare Costs of Melanoma and Keratinocyte Skin Cancers in Australia and Aotearoa New Zealand in 2021. Int J Environ Res Public Health 2022;19:3178. [PMID: 35328865 DOI: 10.3390/ijerph19063178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Witt RG, Erstad DJ, Wargo JA. Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials. Ther Adv Med Oncol 2022;14:175883592210830. [DOI: 10.1177/17588359221083052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Dawidowska A, Jagodzinska-Mucha P, Koseła-Paterczyk H, Jaczewska S, Sobczuk P, Chelstowska M, Kowalska M, Badziak-Sterczewska H, Poleszczuk J, Rutkowski P, Lugowska I. Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma. Cancers (Basel) 2022;14:1248. [PMID: 35267557 DOI: 10.3390/cancers14051248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Queiroz MM, Bertolli E, Belfort FA, Munhoz RR. Management of In-Transit Metastases. Curr Oncol Rep 2022. [PMID: 35192119 DOI: 10.1007/s11912-022-01216-0] [Reference Citation Analysis]
31 Sabbatino F, Liguori L, Pepe S, Ferrone S. Immune checkpoint inhibitors for the treatment of melanoma. Expert Opin Biol Ther 2022. [PMID: 35130816 DOI: 10.1080/14712598.2022.2038132] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Schmitt AM, Dumas L, Larkin J. Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma. Expert Rev Anticancer Ther 2022;:1-9. [PMID: 34904502 DOI: 10.1080/14737140.2022.2017286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Rhodin KE, Baecher K, Mehtsun WT, Lowe M, Boland G, Beasley GM. The Role of Surgery in Managing Primary and Metastatic Melanoma. Cancer Metastasis Through the Lymphovascular System 2022. [DOI: 10.1007/978-3-030-93084-4_36] [Reference Citation Analysis]
34 Nigi A, Toyoshima H, Kondo S, Tanigawa M. Primary melanoma in the bronchus. Clin Case Rep 2021;9:e05192. [PMID: 34938558 DOI: 10.1002/ccr3.5192] [Reference Citation Analysis]
35 Guo W, Wang H, Li C. Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther 2021;6:424. [PMID: 34924562 DOI: 10.1038/s41392-021-00827-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
36 Nakamura Y, Namikawa K, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Fujimoto N, Kuwatsuka Y, Onishi M, Kaneko T, Onuma T, Umeda Y, Ogata D, Takahashi A, Otsuka M, Teramoto Y, Yamazaki N. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study). ESMO Open 2021;6:100325. [PMID: 34839104 DOI: 10.1016/j.esmoop.2021.100325] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
37 Fowler D, Nattress C, Navarrete AS, Barisa M, Fisher J. Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment. Cancers (Basel) 2021;13:6000. [PMID: 34885108 DOI: 10.3390/cancers13236000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Zeng H, Liu F, Zhou H, Zeng C. Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going? Front Oncol 2021;11:775100. [PMID: 34804979 DOI: 10.3389/fonc.2021.775100] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Khaddour K, Maahs L, Avila-Rodriguez AM, Maamar Y, Samaan S, Ansstas G. Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches. Cancers (Basel) 2021;13:5847. [PMID: 34831002 DOI: 10.3390/cancers13225847] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Zhang Y, La B, Liang B, Gu Y. Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. Life (Basel) 2021;11:1277. [PMID: 34833153 DOI: 10.3390/life11111277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Rossi E, Schinzari G, Maiorano BA, Esposito I, Acampora A, Romagnoli J, Stefani AD, Regno LD, Lancellotta V, Fionda B, Tagliaferri L, Peris K, Tortora G. Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review. Immunotherapy 2021. [PMID: 34751039 DOI: 10.2217/imt-2021-0195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Scarpato L, Festino L, Vanella V, Madonna G, Mastroianni M, Palla M, Ascierto PA. Dermatologic adverse events associated with targeted therapies for melanoma. Expert Opin Drug Saf 2021;:1-11. [PMID: 34595993 DOI: 10.1080/14740338.2022.1986000] [Reference Citation Analysis]
43 Lai X, Zhou J, Wessely A, Heppt M, Maier A, Berking C, Vera J, Zhang L. A disease network-based deep learning approach for characterizing melanoma. Int J Cancer 2021. [PMID: 34716589 DOI: 10.1002/ijc.33860] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
44 Janopaul-Naylor JR, Shen Y, Qian DC, Buchwald ZS. The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances. Int J Mol Sci 2021;22:11061. [PMID: 34681719 DOI: 10.3390/ijms222011061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
45 Zimmer L, Livingstone E, Krackhardt A, Schultz ES, Göppner D, Assaf C, Trebing D, Stelter K, Windemuth-Kieselbach C, Ugurel S, Schadendorf D. Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial. Eur J Cancer 2021;158:72-84. [PMID: 34655839 DOI: 10.1016/j.ejca.2021.09.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
46 Quaglino P, Fava P, Tonella L, Rubatto M, Ribero S, Fierro MT. Treatment of Advanced Metastatic Melanoma. Dermatol Pract Concept 2021;11:e2021164S. [PMID: 34447613 DOI: 10.5826/dpc.11S1a164S] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
47 Pietrantonio F, Lonardi S, Corti F, Infante G, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Curigliano G, Cremolini C, Ambrosini M, Ros J, Intini R, Nappo F, Damian S, Morano F, Fucà G, Overman M, Miceli R. Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer 2021;9:e003370. [PMID: 34429334 DOI: 10.1136/jitc-2021-003370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Proctor M, Gonzalez Cruz JL, Daignault-Mill SM, Veitch M, Zeng B, Ehmann A, Sabdia M, Snell C, Keane C, Dolcetti R, Haass NK, Wells JW, Gabrielli B. Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression. Cancers (Basel) 2021;13:3733. [PMID: 34359633 DOI: 10.3390/cancers13153733] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
49 Dalle S, Mortier L, Corrie P, Lotem M, Board R, Arance AM, Meiss F, Terheyden P, Gutzmer R, Buysse B, Oh K, Brokaw J, Le TK, Mathias SD, Scotto J, Lord-Bessen J, Moshyk A, Kotapati S, Middleton MR. Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study. BMC Cancer 2021;21:642. [PMID: 34051732 DOI: 10.1186/s12885-021-08032-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
50 Saputro RD, Rinonce HT, Iramawasita Y, Ridho MR, Pudjohartono MF, Anwar SL, Setiaji K, Aryandono T. Potential prognostic value of PD-L1 and NKG2A expression in Indonesian patients with skin nodular melanoma. BMC Res Notes 2021;14:206. [PMID: 34049578 DOI: 10.1186/s13104-021-05623-7] [Reference Citation Analysis]
51 Wessely A, Steeb T, Berking C, Heppt MV. How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance. Int J Mol Sci 2021;22:5761. [PMID: 34071193 DOI: 10.3390/ijms22115761] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
52 Awada G, Jansen Y, Schwarze JK, Tijtgat J, Hellinckx L, Gondry O, Vermeulen S, Warren S, Schats K, van Dam PJ, Kockx M, Keyaerts M, Everaert H, Seremet T, Rogiers A, Neyns B. A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. Cancers (Basel) 2021;13:E168. [PMID: 33418936 DOI: 10.3390/cancers13020168] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
53 Serzan M, Atkins MB, Lombardi Comprehensive Cancer Center, Washington, DC, USA, Georgetown University Medical Center, Washington, DC, USA, MedStar Georgetown University Hospital, Washington, DC, USA, Lombardi Comprehensive Cancer Center, Washington, DC, USA, Georgetown University Medical Center, Washington, DC, USA, MedStar Georgetown University Hospital, Washington, DC, USA. Lymphocyte-activation Gene 3 and Programmed Cell Death 1 Checkpoint Inhibition as a Novel Combination in Advanced Melanoma. Oncology & Haematology 2021;17:58. [DOI: 10.17925/ohr.2021.17.2.58] [Reference Citation Analysis]